The same results were observed after induction of ERβ expression in a prostate cancer cell line in a study that followed the same idea of our work about using a triple therapy of epigenetic drugs and ERβ agonist (decitabine + trichostatin A + DPN) [14]. Here, ESR2 is linked to prostate carcinoma.